CSIMarket
 
Rigel Pharmaceuticals Inc  (RIGL)
Other Ticker:  
 
 
Price: $1.3600 $0.03 2.256%
Day's High: $1.425 Week Perf: -9.93 %
Day's Low: $ 1.30 30 Day Perf: 15.25 %
Volume (M): 1,279 52 Wk High: $ 1.96
Volume (M$): $ 1,740 52 Wk Avg: $1.23
Open: $1.31 52 Wk Low: $0.71



 Market Capitalization (Millions $) 237
 Shares Outstanding (Millions) 174
 Employees 135
 Revenues (TTM) (Millions $) 132
 Net Income (TTM) (Millions $) -24
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 15

Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals Inc. is a biotechnology company that is based in South San Francisco, California. It is a publicly-traded company that is listed on the NASDAQ stock exchange under the ticker symbol RIGL. The company specializes in the research and development of novel drugs for the treatment of several diseases such as thrombocytopenia, immune diseases, and cancer, among others.

Rigel Pharmaceuticals was founded in 1996 and has been a pioneer in the development of therapies for immune diseases. The company's primary focus is on the discovery, design, and development of small molecule drugs that can modulate signaling pathways that regulate immune function. Rigel's drug candidates target the signaling pathways associated with the T-cell receptor, B-cell receptor, and chemokine receptors.

The company has a robust drug discovery platform that is built upon its deep understanding of the biology of the immune system. Rigel's scientists utilize a combination of technologies such as high-throughput screening, medicinal chemistry, and structural biology to identify and optimize drug candidates. The company has a strong intellectual property portfolio that includes patents and patent applications covering its drug candidates.

Rigel Pharmaceuticals has several drug candidates in clinical development. Its lead product candidate, fostamatinib disodium (Tavalisse), has been approved by the US FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Fostamatinib is a spleen tyrosine kinase (SYK) inhibitor that can modulate the immune response.

In addition to fostamatinib, Rigel has several other drug candidates in clinical development. These include R835 (a dual spleen tyrosine kinase and Janus kinase (JAK) inhibitor) for the treatment of autoimmune diseases such as rheumatoid arthritis, and R552 (an inhibitor of receptor activator of nuclear factor kappa-B ligand (RANKL)) for the treatment of osteoporosis.

Rigel Pharmaceuticals has partnerships with several pharmaceutical companies to develop and commercialize its drug candidates. These include AstraZeneca for fostamatinib and BerGenBio for a cancer drug candidate. The company has also received funding from government agencies such as the National Institutes of Health and the Defense Advanced Research Projects Agency.

In conclusion, Rigel Pharmaceuticals is a biotechnology company that focuses on the discovery and development of drugs for the treatment of immune diseases, cancer, and other conditions. The company has a strong drug discovery platform based on its deep understanding of the immune system, and it has a pipeline of drug candidates in clinical development. With several partnerships and a strong intellectual property portfolio, Rigel is poised for continued growth in the biopharmaceutical industry.


   Company Address: 611 Gateway Boulevard, Suite 900, South San Francisco 94080 CA
   Company Phone Number: 624-1100   Stock Exchange / Ticker: NASDAQ RIGL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc's Earnings Season: A Roller Coaster Ride of Redemption and Caution



In the face of a recent surge in Rigel Pharmaceuticals Inc's (RIGL) share price, driven by positive financial indicators, a closer analysis reveals concerning trends that suggest caution for potential investors. While the company has shown some improvement in revenue and earnings per share (EPS), there are other fundamental factors that paint a bearish outlook.
Persistent Losses and Net Deficit
Despite a decrease in losses per share compared to the previous year, Rigel Pharmaceuticals Inc still recorded a loss per share of $-0.03, signifying the company's inability to generate consistent profits. Furthermore, the reported net deficit of $-5.692 million in the third quarter of 2023 earnings season, as opposed to a deficit of $-19.037 million in the same period a year ago, highlights ongoing financial challenges.

Rigel Pharmaceuticals Inc

Fiscal Storm 2023: Rigel Pharmaceuticals Grapples with Waning Revenues and Escalating Deficits!

The stock market can sometimes be a rollercoaster ride, with ups and downs that keep investors on their toes. However, there is always light at the end of the tunnel, and in the case of Rigel Pharmaceuticals Inc, the future looks promising.
In the second quarter of 2023, Rigel Pharmaceuticals Inc managed to decrease their loss per share to a mere $-0.04 per share, a significant improvement from the previous reporting season. This positive development can be attributed to their efforts in reducing turnover and focusing on revenue growth. Although their revenue took a dip by -9.836% to $26.89 million, it is important to note that this is a year-on-year comparison. In comparison to the Major Pharmaceutical Preparations sector, Rigel Pharmaceuticals Inc actually recorded a revenue gain of 3.78%, showcasing their resilience in a challenging market.

Rigel Pharmaceuticals Inc

An Outstanding 55.781%, rise in revenue at Rigel Pharmaceuticals Inc amid the most recent fiscal period

Rigel Pharmaceuticals Inc is a biotechnology company that specializes in discovering, developing, and commercializing novel small molecule drugs. The company is focused on developing drugs for patients with immune and hematologic disorders, cancer, and rare diseases.
However, in the first quarter of 2023, Rigel Pharmaceuticals Inc recorded a cumulative net loss of $-45 million, resulting in a negative return on assets (ROA) of -35.62%. This means that the company's assets, including investments, equipment, and patents, have not generated sufficient revenue or profit.






 

Rigel Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com